Перейти к основному содержанию
AkademIndex

Продукты

Для разработчиков

AkademBaseОткрытый API экосистемы
Статья

Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy

Mengze LvJill Roberts Institute for Research in Inflammatory Bowel Disease (JRI), Weill Cornell Medicine, Cornell University, New York, NY, USAMeixia ChenDepartment of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, 100853, ChinaRui ZhangKey Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking University, Beijing, 100871, ChinaWen ZhangInstitute for Immunology, Peking-Tsinghua Center for Life Sciences, School of Medicine, Tsinghua University, Beijing, 100084, ChinaChenguang WangKey Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking University, Beijing, 100871, ChinaYan ZhangDepartment of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, 100853, ChinaXiaoming WeiKey Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking University, Beijing, 100871, ChinaYukun GuanExperimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USAJiejie LiuDepartment of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, 100853, ChinaKaichao FengDepartment of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, 100853, ChinaMiao JingKey Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking University, Beijing, 100871, ChinaXurui WangKey Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking University, Beijing, 100871, ChinaYun‐Cai LiuInstitute for Immunology, Peking-Tsinghua Center for Life Sciences, School of Medicine, Tsinghua University, Beijing, 100084, ChinaQian MeiDepartment of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, 100853, China. [email protected]Weidong HanDepartment of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, 100853, China. [email protected]Zhengfan JiangKey Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking University, Beijing, 100871, China. [email protected]
2020en
ABI

Аннотация

Abstract CD8 + T cell-mediated cancer clearance is often suppressed by the interaction between inhibitory molecules like PD-1 and PD-L1, an interaction acts like brakes to prevent T cell overreaction under normal conditions but is exploited by tumor cells to escape the immune surveillance. Immune checkpoint inhibitors have revolutionized cancer therapeutics by removing such brakes. Unfortunately, only a minority of cancer patients respond to immunotherapies presumably due to inadequate immunity. Antitumor immunity depends on the activation of the cGAS-STING pathway, as STING-deficient mice fail to stimulate tumor-infiltrating dendritic cells (DCs) to activate CD8 + T cells. STING agonists also enhance natural killer (NK) cells to mediate the clearance of CD8 + T cell-resistant tumors. Therefore STING agonists have been intensively sought after. We previously discovered that manganese (Mn) is indispensable for the host defense against cytosolic dsDNA by activating cGAS-STING. Here we report that Mn is also essential in innate immune sensing of tumors and enhances adaptive immune responses against tumors. Mn-insufficient mice had significantly enhanced tumor growth and metastasis, with greatly reduced tumor-infiltrating CD8 + T cells. Mechanically, Mn 2+ promoted DC and macrophage maturation and tumor-specific antigen presentation, augmented CD8 + T cell differentiation, activation and NK cell activation, and increased memory CD8 + T cells. Combining Mn 2+ with immune checkpoint inhibition synergistically boosted antitumor efficacies and reduced the anti-PD-1 antibody dosage required in mice. Importantly, a completed phase 1 clinical trial with the combined regimen of Mn 2+ and anti-PD-1 antibody showed promising efficacy, exhibiting type I IFN induction, manageable safety and revived responses to immunotherapy in most patients with advanced metastatic solid tumors. We propose that this combination strategy warrants further clinical translation.

Перевод пока недоступен

Идентификаторы

Цитирования и источники

Цитирований: 2Использованных источников: 0